What improvements would you like in Yahoo! Finance Message Boards? Please send us feedback.
Message Boards Settings Novo-Nordisk A/S (NVO) - Quote Info
great view     26-Oct-09 11:13 am    
Novo Nordisk A/S (ADR) (NYSE:NVO) has made an announcement that their diabetes treatment Liraglutide cuts weight and reduces health risks in obese non-diabetics. The Denmark-based healthcare company unveiled a set of new data that demonstrated that its Type 2 diabetes drug Victoza is far more effective than Roche’s Xenical in cutting weight and losing blood pressure. Novo Nordisk has already applied for the New Drug Application however; it has not been reviewed by the Food and Drug Administration panel. Novo Nordisk is into the manufacturing and marketing of pharmaceutical products and services to patients who are suffering from diabetes.

http://www.favstocks.com/novo-nordisk-ra...
Rating :
 (No ratings)
Rate it:
awful/not related to \pooraveragegoodexcellent

liont10


View Messages

Ignore User

Report Abuse

< Previous Message |   Next Message >
View: Simple | Summary | Expanded
As: Threaded | Msg List
Page 1 of about 1   First | < Prev | Next > | Last

Messages in Topic

Minimum rating: What's this?
  Subject Author Rating Time of Post (ET)  
 
great view
liont10 Not rated 26-Oct-09 11:13 am  
View: Simple | Summary | Expanded
As: Threaded | Msg List
Page 1 of about 1   First | < Prev | Next > | Last

Novo Nordisk A/S (NVO)

Chart for Novo Nordisk A/S (NVO)
On Nov 24: 65.21 0.00 (0.00%)
Symbol Lookup